Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies

Eur J Med Chem. 2022 May 21;238:114468. doi: 10.1016/j.ejmech.2022.114468. Online ahead of print.ABSTRACTNLRP3 inflammasome dysregulation has been observed in many human diseases including neurodegenerative disorders. Thus, development of small molecule inhibitors targeting this protein complex represents a promising strategy to achieve disease intervention. In our continuing efforts to develop NLRP3 inhibitors, a recently identified lead inhibitor, YQ128, was further modified and optimized. The structure-activity relationship studies of this lead compound suggested its flexibility for structural modifications while the sulfonamide and benzyl moiety demonstrated being important for selectivity. Additionally, the systematic SAR studies also provided insights for designing NLRC4 and AIM2 inflammasome inhibitors. A new lead inhibitor, 19, was identified with improved potency (IC50: 0.12 ± 0.01 μM) and binding affinity (KD: 84 nM). Further characterization of this lead compound using wild type and nlrp3-/- mice confirmed its in vivo selective target engagement. PET studies using a radiotracer based on the structure of 19 also demonstrated its improved brain penetration compared to previous lead compounds. These results strongly encourage further testing of 19 in disease models.PMID:35635948 | DOI:10.1016/j.ejmech.2022.114468
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
More News: Brain | Chemistry | Neurology | Study